Skip Navigation


Rheumatology Advance Access originally published online on July 13, 2004
Rheumatology 2004 43(10):1283-1287; doi:10.1093/rheumatology/keh312
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
43/10/1283    most recent
keh312v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (11)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Bodman-Smith, M. D.
Right arrow Articles by Panayi, G. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bodman-Smith, M. D.
Right arrow Articles by Panayi, G. S.
Related Collections
Right arrow Rheumatoid Arthritis
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Rheumatology Vol. 43 No. 10 © British Society for Rheumatology 2004; all rights reserved

Paper

Antibody response to the human stress protein BiP in rheumatoid arthritis

M. D. Bodman-Smith, V. M. Corrigall, E. Berglin1, H. R. Cornell, A. G. Tzioufas2, C. P. Mavragani2, C. Chan, S. Rantapää-Dahlqvist1 and G. S. Panayi

Department of Rheumatology, GKT School of Medicine, King's College London, Guy's Hospital, London SE1 9RT, UK, 1 Department of Rheumatology, University Hospital, Umeå, Sweden and 2 Department of Pathophysiology, School of Medicine, University of Athens, Greece.

Correspondence to: M. Bodman-Smith, St George's Hospital Medical School, London SW17 0RE, UK. E-mail: mbodmans{at}sghms.ac.uk

Objectives. The human stress protein BiP (immunoglobulin binding protein) has been implicated in the pathogenesis of rheumatoid arthritis (RA) since BiP was found to stimulate synovial T-cell proliferation and anti-BiP antibodies are present in the serum of RA patients. The aim of this study was the development of a rapid and reproducible enzyme-linked immunosorbent assay (ELISA) to determine the specificity and sensitivity of anti-BiP antibodies in RA.

Methods. An ELISA was developed that detected antibodies to BiP. The prevalence of anti-BiP antibodies was determined in sera from patients with early and established RA, sera antedating the onset of RA and sera from patients with other inflammatory and autoimmune diseases and healthy controls.

Results. We have confirmed the increased prevalence of antibodies to BiP in the sera of a large cohort of patients with established RA (specificity 71% and sensitivity 73%) and early RA (specificity 65% and sensitivity 66%). In pre-disease sera, median 2.5 yr (interquartile range 1.1–4.7) before symptoms of joint disease, the sensitivity for anti-BiP antibodies was 45% and the specificity was 65% for the development of RA.

Conclusion. Antibodies to BiP are found in the sera of patients with RA and in sera antedating the onset of RA.

KEY WORDS: Rheumatoid arthritis, Heat shock protein, Antibodies, ELISA


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Rheumatology (Oxford)Home page
M. D. Bodman-Smith, M. F. Fife, H. Wythe, V. M. Corrigal, G. S. Panayi, L. R. Wedderburn, and P. Woo
Anti-BiP antibody levels in juvenile idiopathic arthritis (JIA)
Rheumatology, October 1, 2004; 43(10): 1305 - 1306.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.